Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]
18 new portfolio investments Five portfolio companies acquired $766 million invested and committed $600 million of cash exit proceeds San Francisco, Boston, London, and Copenhagen, Denmark, 5 March 2024 – The Novo Holdings Venture Investments team today published its review of 2023 – a record year advancing innovative therapies for patients. Read more…
COPENHAGEN and SINGAPORE, February 6 – Novo Holdings today announced its investment in Manipal Hospitals (‘Manipal’), which constitutes Novo Holding’s largest investment in Asia to date. Manipal Hospitals is among the top healthcare providers in India, providing comprehensive curative and preventive care for a multitude of patients within India and from around the globe. Read more…
COPENHAGEN and SINGAPORE. Novo Holdings today announced its investment in Medi Assist, India’s largest health benefits’ administrator. The investment marks Novo Holdings Asia Investments’ fourth investment in HealthTech, a sector subject to robust growth across the APAC region, and the fifth investment in India. Read more…
Tenmile and Novo Holdings are core investors Cristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of Directors Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organisms SAN FRANCISCO, Jan. 5, 2024 – Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced […]
